Abbott Strikes $670 Million Deal to Settle Premature Infant Formula Lawsuits — BigGo Finance
Abbott Laboratories (ABT) agreed to pay $670 million to settle around 2,000 lawsuits related to its premature infant formulas, including a $495 million verdict. The company denies wrongdoing but aims to resolve broader litigation. Abbott faces additional lawsuits, with a Chicago federal judge overseeing over 825 cases. Analysts suggest this settlement may set a precedent for future cases.
How this was made
The 30-second read
Why it matters
The $670 million settlement resolves a subset of claims, potentially lowering legal expenses and improving earnings guidance.
Market read
Settlement removes a major litigation cloud, likely supporting Abbott's stock price in the short term.
What to watch
Potential future claims and the cost of ongoing litigation could still affect cash flow.
Background
Abbott faces thousands of lawsuits alleging its premature infant formulas cause necrotizing enterocolitis.
Ticker impact
Abbott Laboratories announced a $670 million settlement to resolve ~2,000 premature infant formula lawsuits.
Potential short‑term price uplift as uncertainty resolves.
Large, previously undisclosed settlement removes litigation risk and may be viewed favorably by investors.
Market effects
Reduces legal risk exposure for the medical devices and nutrition segment.
May slightly boost US healthcare stocks as litigation risk eases.
Limited to companies with similar infant‑formula product lines.
Counterpoint
Some investors may view the settlement as a sign of deeper product liability concerns.
Key entities
- CompanyAbbott Laboratories
US‑listed healthcare company (ticker ABT).
- PlaintiffMargo Gill
Mother whose lawsuit led to a $495 million jury verdict.
